Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07450716 · ClinicalTrials.gov registry record · Early Phase 1
Assessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus
A Early Phase 1 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT07450716: Clinical Trial Early Phase 1 study, sponsored by Massachusetts General Hospital.
NCT07450716 is a Early Phase 1 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07450716, a Early Phase 1 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and effectiveness of a low-level near-infrared LED light device for relieving itch. The device is non-invasive, does not break the skin, and does not produce heat. Near-infrared light has been used in other medical settings and is known to interact with skin and nerve pathways. In this study, researchers are examining whether this light can be safely applied to the skin and whether it may help reduce itch by affecting signals involved in itch sensation.
Interventions
- OTHER Placebo
- DEVICE Light-emitting diode (LED) Photobiomodulation (PBM) device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-04 |
| Est. Completion | 2026-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07450716
The ClinicalTrials.gov registry entry for NCT07450716 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07450716 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07450716 about?
NCT07450716 is a clinical study titled "Assessing the Efficacy and Safety of Photobiomodulation for the Treatment of Pruritus". This study is designed to evaluate the safety and effectiveness of a low-level near-infrared LED light device for relieving itch. The device is non-invasive, does not break the skin, and does not produce heat. Near-infrared light has been used in other medical settings and is known to interact with ...
What is the current status of trial NCT07450716?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2026-04. Estimated completion is 2026-12.
What interventions are being tested in trial NCT07450716?
The interventions under investigation include: Placebo (OTHER), Light-emitting diode (LED) Photobiomodulation (PBM) device (DEVICE).
Who is sponsoring clinical trial NCT07450716?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.